Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.230
-0.010-0.11%
Volume:59.56M
Turnover:549.93M
Market Cap:106.35B
PE:23.29
High:9.320
Open:9.130
Low:9.110
Close:9.240
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.46
T/O Rate:0.52%
Dividend:0.29
Dividend Rate:3.14%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.42
PE(LYR):23.29
PS:2.91

Loading ...

CSPC Pharmaceutical Group Stock Rallies 4.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 20

Movement Alert|CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery

Market Focus
·
Jul 20

CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 17

CSPC Pharmaceutical’s Trastuzumab Envedotin NDA Accepted by China’s NMPA

Bulletin Express
·
Jul 17

CSPC Pharma's New Drug Application for Envituzumab Injection Accepted by Chinese Regulator

Stock News
·
Jul 17

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Trastuzumab Envedotin Injection

THOMSON REUTERS
·
Jul 17

CSPC Pharmaceutical - Product Indicated for Unresectable or Metastatic Her2-positive Breast Cancer in Adults

THOMSON REUTERS
·
Jul 17

Movement Alert|CSPC Pharmaceutical Falls 3.02% in Regular Trading, Trading at HKD 8.22

Market Focus
·
Jul 17

CSPC Pharma Begins Two Drug Trials in China

MT Newswires Live
·
Jul 16

CSPC PHARMA Initiates Phase II Trial in China for Novel Sirolimus Formulation in Rare Vascular Tumor

Stock News
·
Jul 16

CSPC PHARMA's Phase III Trial for SYS 6043 in Platinum-Resistant Gynecologic Cancers Commences at First Chinese Site

Stock News
·
Jul 16

CSPC Pharmaceutical Initiates China Phase II Trial of Albumin-bound Sirolimus Injection for Epithelioid Haemangioendothelioma

Reuters
·
Jul 16

CSPC Pharmaceutical Initiates China Phase III Trial of Sys6043 in Platinum-resistant Ovarian Cancer

Reuters
·
Jul 16

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong

Dow Jones
·
Jul 16

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation

Market Focus
·
Jul 16

CSPC Pharmaceutical Group Stock Rises 3.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 15

Movement Alert|CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer

Market Focus
·
Jul 15

CSPC Pharma’s Albumin-Bound Docetaxel and Anbenitamab Secure China Breakthrough Therapy Status for First-Line HER2-Positive Breast Cancer

Bulletin Express
·
Jul 14

Mutual Fund Boosts Stake in Pharmaceutical Giant with Multi-Million Dollar Purchase

Stock News
·
Jul 14

CSPC Says China Regulator Grants Breakthrough Therapy Designation for Her2-positive Breast Cancer Combo

Reuters
·
Jul 14